AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...

The FTSE 100 rebounded after a near three-week low, boosted by gains in healthcare and industrial mining sectors. AstraZeneca's positive drug trial results and rebounding copper prices fueled the rise ...

LONDON/NEW YORK (Reuters) -Drugmakers are lobbying U.S. President Donald Trump to phase in tariffs on imported pharmaceutical ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

European stocks rebounded, snapping four days of losses, as investors maintained their focus on upcoming US tariffs.